Together, this indicates that N-MYC cooperates with EZH2 to drive the neuroendocrine phenotype in prostate cancer, thereby providing a rationale for therapeutic strategies targeting EZH2 [103]. This evidence concerns the gene EZH2 and prostate carcinoma.